#United States #Salt Lake City #Sera Prognostics #PreTRM #maternal healthcare

Sera Prognostics Announces $50 Million Public Offering

SALT LAKE CITY, Feb. 10, 2025 – Sera Prognostics, Inc., more famously recognized as The Pregnancy Company®, has taken significant strides to further its mission of enhancing maternal and neonatal health. By offering a public offering of approximately $50 million, Sera is set to bolster its resources and expand its operational capabilities significantly.

The company has priced its offering at $4.00 per share for 1,250,000 shares of its Class A common stock, and it is also providing pre-funded warrants for investors to acquire an additional 11,250,000 shares at $3.9999 each. This tactical move is anticipated to generate substantial gross proceeds, enabling Sera to productively utilize these funds for various strategic initiatives.

Expanding Capabilities and Addressing Needs

In its continuous quest to provide essential pregnancy biomarker information, Sera plans to channel the proceeds into several critical areas. Key objectives include:
1. Enhancing U.S. Operations: Expanding commercial infrastructure domestically to optimize service delivery.
2. Infrastructure Development in Europe: Preparing for growth opportunities within the European Union.
3. Supporting the PreTRM Test: Funding further studies aimed at boosting adoption rates of the revolutionary PreTRM test, which forecasts premature birth risk. This includes plans for a potential submission to the FDA seeking widespread approval.

Sera's dedication to improving healthcare delivery costs significantly by offering predictive insights to expectant mothers and healthcare providers underscores its important role in the medical field.

Strategic Partnerships and Future Prospects

This public offering, led by Jefferies, TD Cowen, and William Blair as joint book-running managers, with RBC Capital Markets serving as the bookrunner, comes at a time when Sera is poised to make impactful advancements. The company has also granted the underwriters a 30-day option to buy another 1,875,000 shares of common stock, securing flexibility in its capital raising efforts.

The anticipated closing date for this offering is February 12, 2025, provided that the usual closing conditions are met.

Sera's Vision and Helping Hands

Headquartered in Salt Lake City, Utah, Sera Prognostics focuses on offering innovative diagnostic solutions that anticipate challenges during pregnancy. Its PreTRM® test is a prime example, presenting individualized risk assessments to healthcare practitioners, enabling timely interventions that could save lives. This strategic offering aligns with Sera's overarching mission of advancing healthcare specifically tailored for mothers and their newborns.

Conclusion

As Sera Prognostics embarks on this new chapter in its growth, the implications for maternal healthcare are monumental. With a commitment to innovation, precision medicine, and better health outcomes, Sera is set to redefine the landscape of pregnancy care. The expected influx of capital will not only enhance its operational acumen but will also serve as a beacon of hope for many mothers facing uncertainties during their pregnancy journey.

For those interested, detailed information regarding the public offering, including prospectuses, is available through the Securities and Exchange Commission's website, ensuring full transparency and regulatory compliance. Sera continues to emphasize its mission, strategically laying the groundwork for a brighter, healthier future for women and families globally.